お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:固形腫瘍検査の世界市場 (2019-2030年):技術・癌の種類・用途・エンドユーザー・競合情勢
市場調査レポート
商品コード
999052

固形腫瘍検査の世界市場 (2019-2030年):技術・癌の種類・用途・エンドユーザー・競合情勢

Global Solid Tumor Testing Market: Focus on Technology, Cancer Type, Application, End User, and Competitive Landscape - Analysis and Forecast, 2019-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 238 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
固形腫瘍検査の世界市場 (2019-2030年):技術・癌の種類・用途・エンドユーザー・競合情勢
出版日: 2021年04月05日
発行: BIS Research Inc.
ページ情報: 英文 238 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の固形腫瘍検査の市場規模は予測期間中6.09%のCAGRで推移し、2030年には406億米ドルの規模に成長すると予測されています。

診断、予後、治療など、さまざまなな用途の癌研究において、次世代シーケンサー、in situハイブリダイゼーション、PCRなどの技術に基づく先進的ソリューションの開発ニーズが高まっており、同市場の成長を推進しています。

当レポートでは、世界の固形腫瘍検査の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、償還動向、市場規模の推移・予測、技術・癌の種類・用途・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 製品の定義

第2章 市場の範囲

第3章 調査手法

第4章 市場概要

第5章 産業考察

  • 遺伝子検査の規制
  • 法的要件・枠組み:欧州
  • 法的要件・枠組み:アジア太平洋
  • 償還シナリオ

第6章 市場力学

  • 影響分析
  • 市場推進因子
  • 市場抑制因子
  • 市場機会

第7章 競合情勢

  • 主な戦略・展開
  • 製品シナリオ
  • 市場シェア分析

第8章 市場分析・予測:技術別

  • 概要
  • 次世代シーケンシング
  • in situハイブリダイゼーション
  • ポリメラーゼ連鎖反応
  • 免疫組織化学
  • その他

第9章 市場分析・予測:癌の種類別

  • 概要
  • 乳癌
  • 前立腺癌
  • 結腸直腸癌
  • 肺癌
  • 黒色腫
  • 子宮内膜癌
  • 甲状腺癌
  • 脳腫瘍
  • 卵巣癌
  • 肝臓癌
  • その他

第10章 市場分析・予測:用途別

  • 概要
  • 臨床
  • 研究

第11章 市場分析・予測:地域・主要国別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • シンガポール
    • オーストラリア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • その他の地域

第12章 市場分析・予測:エンドユーザー別

  • 概要
  • 病院・診断ラボ・リファレンスラボ
  • 製薬・バイオテクノロジー企業
  • CRO
  • 学術調査機関
  • その他

第13章 企業プロファイル

  • Abbott Laboratories
  • ARUP Laboratories
  • ASURAGEN, INC.
  • Bio-Rad Laboratories, Inc.
  • Beijing Genomics Institute (BGI) Genomics Co., Ltd
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories, Inc.
  • Opko Health
  • OmniSeq
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
図表

List of Figures

  • Figure 1: Global Cancer Incidence and Prevalence, Cancer Types, 2020
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Solid Tumor Testing Market
  • Figure 3: Global Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030
  • Figure 4: Global Solid Tumor Testing Market (by Cancer Type), $Million, 2020 and 2030
  • Figure 5: Global Solid Tumor Testing Market (by Application), $Million, 2020 and 2030
  • Figure 6: Global Solid Tumor Testing Market (by End User), $Million, 2020 and 2030
  • Figure 2.1: Global Solid Tumor Testing Market Segmentation
  • Figure 3.1: Global Solid Tumor Testing Market Research Methodology
  • Figure 6.1: Cancer Cases Projections, 2015-2020
  • Figure 6.2: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 6.3: Synergistic Activities, 2017-2019
  • Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018
  • Figure 6.5: NCI Fiscal Budget Year on Year, 2013-2018
  • Figure 7.1: Share of Key Strategies and Developments, January 2017-March 2021
  • Figure 7.2: Synergistic Activities Share (by Company), January 2017-March 2021
  • Figure 7.3: Approvals Share (by Company), January 2017-March 2021
  • Figure 7.4: Product Launches, Enhancements and Expansions Share (by Company), January 2017-March 2021
  • Figure 7.5: Acquisitions and Mergers Share (by Company), January 2017-March 2021
  • Figure 7.6: Market Share Analysis for the Global Solid Tumor Testing Market, 2020
  • Figure 7.7: Growth-Share Matrix for Global Solid Tumor Testing Market (by Company), 2020
  • Figure 7.8: Growth Share Matrix for Global Solid Tumor Testing Market (by Technology), 2020
  • Figure 7.9: Growth-Share Matrix for Global Solid Tumor Testing Market (by Application), 2020
  • Figure 7.10: Growth-Share Matrix for Global Solid Tumor Testing Market (by Cancer Type), 2020
  • Figure 8.1: Global Solid Tumor Testing Market (by Technology), $Million, 2019-2030
  • Figure 8.2: Global Solid Tumor Testing Market (NGS), $Million, 2019-2030
  • Figure 8.3: Global Solid Tumor Testing Market (ISH), $Million, 2019-2030
  • Figure 8.4: Global Solid Tumor Testing Market (for PCR), $Million, 2019-2030
  • Figure 8.5: Global Solid Tumor Testing Market (IHC), $Million, 2019-2030
  • Figure 8.6: Global Solid Tumor Testing Market (Other Technologies), $Million, 2019-20230
  • Figure 9.1: Global Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030
  • Figure 9.2: Global Cancer Incidence, 2020
  • Figure 9.3: Global Solid Tumor Testing Market (Breast Cancer), $Million, 2019-2030
  • Figure 9.4: Global Cancer Incidence, 2020
  • Figure 9.5: Global Solid Tumor Testing Market (for Prostate Cancer), $Million, 2019-2030
  • Figure 9.6: Global Cancer Incidence, 2020
  • Figure 9.7: Global Solid Tumor Testing Market (Colorectal Cancer), $Million, 2019-2030
  • Figure 9.8: Global Cancer Incidence, 2020
  • Figure 9.9: Global Solid Tumor Testing Market (for Lung Cancer), $Million, 2019-2030
  • Figure 9.10: Global Cancer Incidence, 2020
  • Figure 9.11: Global Solid Tumor Testing Market (Melanoma), $Million, 2019-2030
  • Figure 9.12: Global Cancer Incidence, 2020
  • Figure 9.13: Global Solid Tumor Testing Market (Endometrial Cancer), $Million, 2019-2030
  • Figure 9.14: Global Cancer Incidence, 2020
  • Figure 9.15: Global Solid Tumor Testing Market (for Thyroid Cancer), $Million, 2019-2030
  • Figure 9.16: Global Cancer Incidence, 2020
  • Figure 9.17: Global Solid Tumor Testing Market (Brain Cancer), $Million, 2019-2030
  • Figure 9.18: Global Cancer Incidence, 2020
  • Figure 9.19: Global Solid Tumor Testing Market (Ovarian Cancer), $Million, 2019-2030
  • Figure 9.20: Global Cancer Incidence, 2020
  • Figure 9.21: Global Solid Tumor Testing Market (for Liver Cancer), $Million, 2019-2030
  • Figure 9.22: Global Solid Tumor Testing Market (for Other Cancer Types), $Million, 2019-2030
  • Figure 10.1: Global Solid Tumor Testing Market (by Application), $Million, 2019-2030
  • Figure 10.2: Global Solid Tumor Testing Market (by Clinical Applications), $Million, 2019-2030
  • Figure 10.3: Global Solid Tumor Testing Market (Research Applications), $Million, 2019-2030
  • Figure 10.4: Global Solid Tumor Testing Market (by Research Applications), $Million, 2019-2030
  • Figure 11.1: Global Solid Tumor Testing Market (by Region), $Million, 2020 and 2030
  • Figure 11.2: Global Solid Tumor Testing Market (by Region), $Million, 2019-2030
  • Figure 11.3: North America Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.4: North America Solid Tumor Testing Market (by Country), $Million, 2019-2030
  • Figure 11.5: North America: Market Dynamics
  • Figure 11.6: U.S. Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.7: Canada Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.8: Total Market Size for North America Solid Tumor Testing Market (by Technology), 2020 and 2030
  • Figure 11.9: Total Market Size for North America Solid Tumor Testing Market (by Cancer), $Million, 2019-2030
  • Figure 11.10: Europe: Market Dynamics
  • Figure 11.11: Europe Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.12: Europe Solid Tumor Testing Market (by Country), $Million, 2019-2030
  • Figure 11.13: Germany Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.14: U.K. Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.15: France Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.16: Italy Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.17: Spain Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.18: Rest-of-Europe (RoE) Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.19: Total Market Size for Europe Solid Tumor Testing Market (by Technology), 2020 and 2030
  • Figure 11.20: Total Market Size for Europe Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030
  • Figure 11.21: Asia-Pacific Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.22: APAC: Market Dynamics
  • Figure 11.23: Asia-Pacific Solid Tumor Testing Market (by Country), $Million, 2019-2030
  • Figure 11.24: China Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.25: Japan Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.26: India Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.27: Singapore Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.28: Australia Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.29: Rest-of-APAC Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.30: Total Market Size for Asia-Pacific Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030
  • Figure 11.31: Total Market Size for Asia Pacific Solid Tumor Testing Market (by Cancer), $Million, 2019-2030
  • Figure 11.32: Latin America Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.33: Latin America: Market Dynamics
  • Figure 11.34: Latin America Solid Tumor Testing Market (by Country), $Million, 2019-2030
  • Figure 11.35: Brazil Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.36: Mexico Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.37: Rest-of-LATAM Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 11.38: Total Market Size for Latin America Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030
  • Figure 11.39: Total Market Size for Latin America Solid Tumor Testing Market (by Cancer), $Million, 2019-2030
  • Figure 11.40: RoW Solid Tumor Testing Market, $Million, 2019-2030
  • Figure 12.1: Global Solid Tumor Testing Market (by End User), $Million, 2019-2030
  • Figure 12.2: Global Solid Tumor Testing Market (Hospitals, Diagnostic Laboratories, and Reference Laboratories), $Million, 2019-2030
  • Figure 12.3: Global Solid Tumor Testing Market (Pharmaceutical and Biotechnology Companies), $Million, 2019-2030
  • Figure 12.4: Global Solid Tumor Testing Market (Contract Research Organization), $Million, 2019-2030
  • Figure 12.5: Global Solid Tumor Testing Market (Academic Research Institutions), $Million, 2019-2030
  • Figure 12.6: Global Solid Tumor Testing Market (Other End Users), $Million, 2019-2030
  • Figure 13.1: Total Number of Companies Profiled
  • Figure 13.2: Abbott Laboratories: Portfolio
  • Figure 13.3: Abbott Laboratories: Overall Financials, 2018-2020
  • Figure 13.4: Abbott Laboratories: Revenue (by Segment), 2018-2020
  • Figure 13.5: Abbott Laboratories: Revenue Split for Diagnostics, 2018-2020
  • Figure 13.6: Abbott Laboratories: Revenue (by Region), 2018-2020
  • Figure 13.7: Abbott Laboratories: R&D Expenditure, 2018-2020
  • Figure 13.8: Abbott Laboratories: SWOT Analysis
  • Figure 13.9: ARUP Laboratories: Portfolio
  • Figure 13.10: ARUP Laboratories: SWOT Analysis
  • Figure 13.11: ASURAGEN, INC.: Portfolio
  • Figure 13.12: ASURAGEN, INC.: SWOT Analysis
  • Figure 13.13: Bio-Rad Laboratories, Inc.: Portfolio
  • Figure 13.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 13.15: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 13.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
  • Figure 13.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 13.18: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 13.19: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Product Portfolio
  • Figure 13.20: Beijing Genomics Institute (BGI) Genomics Co., Ltd.: SWOT Analysis
  • Figure 13.21: F. Hoffmann-La Roche Ltd: Portfolio
  • Figure 13.22: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
  • Figure 13.23: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2018-2020
  • Figure 13.24: F. Hoffmann-La Roche Ltd: Sales (by Region), 2018-2020
  • Figure 13.25: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
  • Figure 13.26: F. Hoffmann-La Roche: SWOT Analysis
  • Figure 13.27: Guardant Health: Portfolio
  • Figure 13.28: Guardant Health: Overall Financials, $Million, 2017-2019
  • Figure 13.29: Guardant Health: Revenue (by Segment), $Million, 2017-2019
  • Figure 13.30: Guardant Health: Revenue (by Region), $Million, 2017-2019
  • Figure 13.31: Guardant Health: SWOT Analysis
  • Figure 13.32: Illumina, Inc.: Portfolio
  • Figure 13.33: Illumina, Inc.: Overall Financials, 2018-2020
  • Figure 13.34: Illumina, Inc.: Revenue (by Segment), 2017-2020
  • Figure 13.35: Illumina, Inc.: Revenue (by Region), 2018-2020
  • Figure 13.36: Illumina, Inc.: R&D Expenditure, 2018-2020
  • Figure 13.37: Illumina, Inc.: SWOT Analysis
  • Figure 13.38: Invivoscribe, Inc.: Portfolio
  • Figure 13.39: Invivoscribe, Inc.: SWOT Analysis
  • Figure 13.40: Invitae Corporation: Portfolio
  • Figure 13.41: Invitae Corporation: Overall Financials, 2018-2020
  • Figure 13.42: Invitae Corporation: Revenue (by Segment), 2018-2020
  • Figure 13.43: Invitae Corporation: Revenue (by Geography), 2018-2020
  • Figure 13.44: Invitae Corporation: R&D Expenditure, 2018-2020
  • Figure 13.45: Invitae Corporation: SWOT Analysis
  • Figure 13.46: Laboratory Corporation of America Holdings: Portfolio
  • Figure 13.47: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2018-2020
  • Figure 13.48: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
  • Figure 13.49: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 13.50: NeoGenomics Laboratories, Inc.: Portfolio
  • Figure 13.51: NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020
  • Figure 13.52: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020
  • Figure 13.53: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020
  • Figure 13.54: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 13.55: Opko Health: Portfolio
  • Figure 13.56: Opko Health: Overall Financials, 2018-2020
  • Figure 13.57: Opko Health: Revenue (by Segment), 2018-2020
  • Figure 13.58: Opko Health: Revenue (by Region), 2018-2020
  • Figure 13.59: Opko Health: R&D Expenditure, 2018-2020
  • Figure 13.60: Opko Health: SWOT Analysis
  • Figure 13.61: OmniSeq: Portfolio
  • Figure 13.62: OmniSeq: SWOT Analysis
  • Figure 13.63: QIAGEN N.V.: Portfolio
  • Figure 13.64: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 13.65: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 13.66: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 13.67: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 13.68: QIAGEN N.V.: SWOT Analysis
  • Figure 13.69: Quest Diagnostics Incorporated: Portfolio
  • Figure 13.70: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 13.71: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
  • Figure 13.72: Quest Diagnostics Incorporated: SWOT Analysis

List of Tables

  • Table 4.1: Solid Tumor Testing Technologies for Clinical Laboratories
  • Table 4.2: Technological Trends in Solid Tumor Testing Market
  • Table 4.3: Industry Participants Landscape in the Global Solid Tumor Testing Market
  • Table 5.1: Examples of New CPT Codes Under the CMS
  • Table 5.2: New Payment Amounts for ADLTs
  • Table 6.1: Likert Scale
  • Table 6.2: Impact Analysis of Market Drivers
  • Table 6.3: Impact Analysis of Market Restraints
  • Table 7.1: Market Players with Key Product Listing
目次
Product Code: BHP1054SA

“Global Solid Tumor Testing Market to Reach $40.6 Billion by 2030.”

Market Report Coverage - Solid Tumor Testing

Market Segmentation

  • Cancer - Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, Brain, Thyroid, Liver, Ovarian and Other
  • Application - Clinical and Research
  • End User - Academic and Research Institutions, Biopharmaceutical and Biotechnological Companies, Contract Research Organizations, and Other End Users

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
  • Latin America - Brazil, Mexico, and Rest-of-the-Latin America
  • Rest-of-the-World

Growth Drivers

  • Rising Incidence of Cancers
  • Decreasing Cost of Sequencing
  • Expected Increase in Adoption of Genetic Testing
  • Increasing Adoption of Inorganic Growth Strategies

Market Challenges

  • Uncertain Reimbursement Policies
  • Requirement of High Capital Investment Hindering Expansion
  • High Pricing Pressure

Market Opportunities

  • Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations
  • Increasing Disposable Income in Emerging Companies
  • Technological Advancements in the Field of Cancer Genomics
  • Mushrooming Direct-to-Consumer Testing Services Market

Key Companies Profiled

Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global solid tumor testing market?
  • What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?
  • What is the current market demand along with future expected demand for the global solid tumor testing market?
  • What are the key development strategies that are implemented by the major players in order to sustain the competitive market?
  • How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segments:
    • cancer type
    • technology
    • application
    • end user
    • region
  • Which are the leading players with significant offerings to the global solid tumor testing market?
  • What is the expected market dominance for each of these leading players?
  • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global solid tumor testing market?

Market Overview

BIS Research healthcare experts have found the solid tumor testing market to be one of the growing markets, which is predicted to grow at a CAGR of 6.09% during the forecast period, 2020-2030. The market is driven by the need for the development of an advanced solution based on various technologies such as next-generation sequencing, in-situ hybridization, and polymerase chain reaction for cancer research in various applications such as diagnosis, prognosis, and treatment.

The market is favored by the development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment. The gradual increase in the prevalence of cancer globally has furthered the solid tumor testing market.

Furthermore, several contract research organizations are focusing on the development of solid tumor testing services, which enable to perform an extensive preclinical study at lower operation costs and less turn-around time.

Within the research report, the market is segmented on the basis of cancer type, technology application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of high-resolution multiplex diagnostics providing information on cellular interaction and tissue heterogeneity to understand disease biology and pathology. Due to technologically advanced solutions and intense market penetration, companies such as Quest Diagnostics Incorporated have been a pioneer and a significant competitor in this market.

Other key players in the market are Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health.

On the basis of region, North America holds the largest share of the global solid tumor testing market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region.

The global solid tumor testing market utilizes technologies such as next-generation sequencing, in-situ hybridization, immunohistochemistry, polymerase chain reaction, and other technologies for the development of advanced diagnostic tools to cater to a holistic approach toward the treatment of cancer. The rising incidence of cancer and the increasing global burden of the disease has subsequently furthered the growth of the market.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Solid Tumors Testing Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Definition
  • 4.2 Solid Tumor Testing Technologies
  • 4.3 Industry Participants Landscape
  • 4.4 Impact of COVID-19 on Delivery of Care for Cancer Patients

5 Industry Insights

  • 5.1 Regulation of Genetic Tests
    • 5.1.1 FDA Regulation
    • 5.1.2 CMS Regulation
  • 5.2 Legal Requirements and Framework in Europe
  • 5.3 Legal Requirements and Framework in Asia-Pacific
    • 5.3.1 China
    • 5.3.2 Japan
  • 5.4 Reimbursement Scenario
    • 5.4.1 Impact on Laboratory Industry

6 Market Dynamics

  • 6.1 Impact Analysis
  • 6.2 Market Drivers
    • 6.2.1 Rising Incidence of Cancers
    • 6.2.2 Decreasing Cost of Sequencing
    • 6.2.3 Increasing Adoption of Inorganic Growth Strategies in the Market
    • 6.2.4 Expected Increase in Adoption of Genetic Testing
  • 6.3 Market Restraints
    • 6.3.1 Uncertain Reimbursement Policies
    • 6.3.2 Requirement of High Capital Investment Hindering Expansion
    • 6.3.3 High Pricing Pressure
  • 6.4 Market Opportunities
    • 6.4.1 Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations
    • 6.4.2 Technological Advancements in the Field of Cancer Genomics
    • 6.4.3 Mushrooming Direct-to-Consumer (DTC) Testing Services Market
    • 6.4.4 Increasing Disposable Income in Emerging Economies

7 Competitive Landscape

  • 7.1 Key Strategies and Developments
    • 7.1.1 Synergistic Activities
    • 7.1.2 Approvals
    • 7.1.3 Product Launches, Enhancements, and Expansions
    • 7.1.4 Acquisitions and Mergers
  • 7.2 Product Scenario
  • 7.3 Market Share Analysis
  • 7.4 Growth-Share Analysis (Opportunity Mapping)
    • 7.4.1 By Company
    • 7.4.2 By Technology
    • 7.4.3 By Application
    • 7.4.4 By Cancer Type

8 Global Solid Tumor Testing Market (by Technology), $Million, 2019-2030

  • 8.1 Overview
  • 8.2 Next-Generation Sequencing
  • 8.3 In Situ Hybridization
  • 8.4 Polymerase Chain Reaction
  • 8.5 Immunohistochemistry
  • 8.6 Other Technologies

9 Global Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030

  • 9.1 Overview
  • 9.2 Breast Cancer
  • 9.3 Prostate Cancer
  • 9.4 Colorectal Cancer
  • 9.5 Lung Cancer
  • 9.6 Melanoma
  • 9.7 Endometrial Cancer
  • 9.8 Thyroid Cancer
  • 9.9 Brain Cancer
  • 9.1 Ovarian Cancer
  • 9.11 Liver Cancer
  • 9.12 Other Cancer Types

10 Global Solid Tumor Testing Market, by Application, $Million, 2019-2030

  • 10.1 Overview
  • 10.2 Clinical
  • 10.3 Research

11 Global Solid Tumor Testing Market (by Region), $Million, 2019-2030

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 U.K.
    • 11.3.3 France
    • 11.3.4 Italy
    • 11.3.5 Spain
    • 11.3.6 Rest-of-Europe
  • 11.4 Asia-Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Singapore
    • 11.4.5 Australia
    • 11.4.6 Rest-of-APAC
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest-of-LATAM
  • 11.6 Rest-of-the-World (RoW)

12 Global Solid Tumor Testing Market, by End User, $Million, 2019-2030

  • 12.1 Overview
  • 12.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories
  • 12.3 Pharmaceutical and Biotechnology Companies
  • 12.4 Contract Research Organizations
  • 12.5 Academic Research Institutions
  • 12.6 Other End Users

13 Company Profiles

  • 13.1 Overview
  • 13.2 Abbott Laboratories
    • 13.2.1 Company Overview
    • 13.2.2 Role of Abbott Laboratories in the Global Solid Tumor Testing Market
    • 13.2.3 Financials
    • 13.2.4 Key Insights About Financial Health of the Company
    • 13.2.5 SWOT Analysis
  • 13.3 ARUP Laboratories
    • 13.3.1 Company Overview
    • 13.3.2 Role of ARUP Laboratories in the Global Solid Tumor Testing Market
    • 13.3.3 SWOT Analysis
  • 13.4 ASURAGEN, INC.
    • 13.4.1 Company Overview
    • 13.4.2 Role of ASURAGEN, INC. in the Global Solid Tumor Testing Market
    • 13.4.3 SWOT Analysis
  • 13.5 Bio-Rad Laboratories, Inc.
    • 13.5.1 Company Overview
    • 13.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Solid Tumor Testing Market
    • 13.5.3 Financials
    • 13.5.4 Key Insights About Financial Health of the Company
    • 13.5.5 SWOT Analysis
  • 13.6 Beijing Genomics Institute (BGI) Genomics Co., Ltd
    • 13.6.1 Company Overview
    • 13.6.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Solid Tumor Testing Market
    • 13.6.3 SWOT Analysis
  • 13.7 F. Hoffmann-La Roche Ltd.
    • 13.7.1 Company Overview
    • 13.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Solid Tumor Testing Market
    • 13.7.3 Financials
    • 13.7.4 Key Insights About Financial Health of the Company
    • 13.7.5 SWOT Analysis
  • 13.8 Guardant Health
    • 13.8.1 Company Overview
    • 13.8.2 Role of Guardant Health in the Global Solid Tumor Testing Market
    • 13.8.3 Financials
    • 13.8.4 SWOT Analysis
  • 13.9 Illumina, Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Role of Illumina, Inc. in the Global Solid Tumor Testing Market
    • 13.9.3 Financials
    • 13.9.4 Key Insights About Financial Health of the Company
    • 13.9.5 SWOT Analysis
  • 13.1 Invivoscribe, Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Role of Invivoscribe, Inc. in the Global Solid Tumor Testing Market
    • 13.10.3 SWOT Analysis
  • 13.11 Invitae Corporation
    • 13.11.1 Company Overview
    • 13.11.2 Role of Invitae Corporation, Inc. in the Global Solid Tumor Testing Market
    • 13.11.3 Financials
    • 13.11.4 Key Insights About Financial Health of the Company
    • 13.11.5 SWOT Analysis
  • 13.12 Laboratory Corporation of America Holdings
    • 13.12.1 Company Overview
    • 13.12.2 Role of Laboratory Corporation of America Holdings in the Global Solid Tumor Testing Market
    • 13.12.3 Financials
    • 13.12.4 SWOT Analysis
  • 13.13 NeoGenomics Laboratories, Inc.
    • 13.13.1 Company Overview
    • 13.13.2 Role of NeoGenomics Laboratories, Inc. in the Global Solid Tumor Testing Market
    • 13.13.3 Financials
    • 13.13.4 Key Insights About Financial Health of the Company
    • 13.13.5 SWOT Analysis
  • 13.14 Opko Health
    • 13.14.1 Company Overview
    • 13.14.2 Role of Opko Health, Inc. in the Global Solid Tumor Testing Market
    • 13.14.3 Financials
    • 13.14.4 Key Insights About Financial Health of the Company
    • 13.14.5 SWOT Analysis
  • 13.15 OmniSeq
    • 13.15.1 Company Overview
    • 13.15.2 Role of OmniSeq in the Global Solid Tumor Testing Market
    • 13.15.3 SWOT Analysis
  • 13.16 QIAGEN N.V.
    • 13.16.1 Company Overview
    • 13.16.2 Role of QIAGEN N.V. in the Global Solid Tumor Testing Market
    • 13.16.3 Financials
    • 13.16.4 Key Insights About Financial Health of the Company
    • 13.16.5 SWOT Analysis
  • 13.17 Quest Diagnostics Incorporated
    • 13.17.1 Company Overview
    • 13.17.2 Role of Quest Diagnostics Limited in the Global Solid Tumor Testing Market
    • 13.17.3 Financials
    • 13.17.4 SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.